Bank Of Nova Scotia Ultragenyx Pharmaceutical Inc. Transaction History

Bank Of Nova Scotia

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $1.48 Million - $1.98 Million	42,451 New	42,451 $1.51 Million
Q1 2023 May 11, 2023	SELL	$36.99 - $48.71 $2.26 Million - $2.97 Million	-61,000 Reduced 61.49%	38,200 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$39.96 - $66.14 $2.43 Million - $4.03 Million	60,897 Added 158.99%	99,200 $4.11 Million
Q2 2022 Aug 08, 2022	BUY	$45.8 - $85.4 $1.75 Million - $3.27 Million	38,303 New	38,303 $2.28 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.